
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Peers & Perspectives in Oncology
In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
CASE SUMMARY
POLLING QUESTION
A decision was made to initiate systemic therapy. What frontline therapy are you most likely to choose for this patient?
over 2 years ago
Treating Rare Driver Mutations in NSCLC: EGFR Exon 20 Insertions